{"name":"De Motu Cordis","slug":"de-motu-cordis","ticker":"","exchange":"","domain":"","description":"Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus, commonly called De Motu Cordis, is the best-known work of the physician William Harvey, which was first published in 1628 and established the circulation of blood throughout the body. It is a landmark in the history of physiology, with Harvey combining observations, experiments, measurements, and hypotheses in an extraordinary fashion to arrive at his doctrine. His work is a model of its kind and had an immediate and far-reaching influence on Harvey's contemporaries; Thomas Hobbes said that Harvey was the only modern author whose doctrines were taught in his lifetime.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EpiPen ®.","genericName":"EpiPen ®.","slug":"epipen","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"EpiPen ®.","genericName":"EpiPen ®.","slug":"epipen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1PQlJITjNYdTNtdHVwUFQ0QXpqYW1LX1RrYWZuWmVvU2hPd1ZpRmZTUVJYZS1HVmFfdk85bi1RUHVfZ0NYaS1KODRIaVozd09MX0VRczE2dE4yR2pWSHNZMlp4VldiUTI0aEh2Um4wSzBKWUh2S2c?oc=5","date":"2025-06-23","type":"pipeline","source":"Future Market Insights","summary":"Inhalation CDMO Market Size, Trends & Growth 2025-2035 - Future Market Insights","headline":"Inhalation CDMO Market Size, Trends & Growth 2025-2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPR2pWbl81a2lPZmNxS0MtSFc2Zk9tMUppRjlNRzRJNDZ6dnNaTWxIRjhaRUFCZWEyQjZOV1JlWG5tU3VRWUtlMGxMZUZHYXFzOHBBZlp3MHhTWFdFd0V5Rmg5OEVYV0ZnUy11VnU1UV9uOUE1Wlo0bnZ2YWJ3Z1I5ZENYRzF3eW9CU0NlYUhJMXUxbzhaZXBnek1zbC1wVjZZRTBRdGlzLUVfVDJ1NGc?oc=5","date":"2024-08-20","type":"regulatory","source":"Biotech Dispatch","summary":"De Motu Cordis welcomes FDA approval of needle-free anaphylaxis treatment - Biotech Dispatch","headline":"De Motu Cordis welcomes FDA approval of needle-free anaphylaxis treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPTzlJdXZxaTNEZWxZYU5UXzBiZXBTT3c2YUNCUzlvdlhlU3hBTzdrS3ZKTGFlVURwdHh0V2U3WnNueFoyQm1jbFpJRWxKaG5xZXBHYUxKdW5BUklJcnItU3Yta3NtWjhiNWpwclB2MVJyei1GVzFSeUpYeE10UGxsSTNkRjVSYUFZbGZMNmdHRkk4RmxFYlBuS0NVUlk2NDNVaXfSAacBQVVfeXFMTjdjbzYzazEtN0pZTk5zT1JnYTMzeElOLTFKY0w3ckR4LVJnUGpwSF9nVGc4a2VjVTNpYXJVaW4zU3FjY0k1NVFKTUd4S3NDM2NpVVM1RnItUkQybjg4dEJWZGVOcGprOFJhbjU4WDAtRFNLbUVvU0ZyX0tDVjVjdHdTRlJIbXpXYi13SkY1OTNHbWhXLVo4eVN3TnNOb3B1T1lXZEY5cWs?oc=5","date":"2021-12-08","type":"pipeline","source":"PBS","summary":"When Diego Rivera used his brush to honor groundbreaking healers - PBS","headline":"When Diego Rivera used his brush to honor groundbreaking healers","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}